黑料网

ISSN: 2475-3173

Cervical Cancer: 黑料网
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

HPV-DNA Screening as a Primary Cervical Cancer Screening Modality in Zimbabwe: Obstacles and Recommendations

Ethel Essel*
Department of Emergency Medicine, Canada
*Corresponding Author: Ethel Essel, Department of Emergency Medicine, Canada, Email: Ethel.e@ualberta.ca

Received Date: Jul 29, 2023 / Published Date: Aug 28, 2023

Citation: Essel E (2023) HPV-DNA Screening as a Primary Cervical Cancer Screening Modality in Zimbabwe: Obstacles and Recommendations. Cervical Cancer, 8: 177.DOI: 10.4172/2475-3173.1000177

Copyright: © 2023 Essel E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The World Health Organisation's 90-70-90 cancer strategy is premised upon the implementation of human papillomavirus deoxyribonucleic acid (HPV-DNA) testing as the primary cervical cancer screening modality. The ultimate aim is to reduce the age-standardized incidence of cervical cancer to less than 4 per 100 000 by the end of the 21st century and eliminate the disease as a significant global health concern. Zimbabwe, like other countries in sub- Saharan Africa, has a high burden of cervical cancer, with data from the Zimbabwe National Cancer Registry showing that cervical cancer is the leading cause of cancer deaths among women. This is despite visual inspection of the cervix with acetic acid (VIA) and cytology being available as screening modalities. These programs have suffered several implementation challenges, and the success of implementing HPV-DNA screening programs will depend partly on addressing the challenges that have been faced by these pre-existing programs. Additionally, other challenges unique to HPV-DNA testing must be anticipated with adequate measures put in place to avert these potential challenges. This calls for a close collaboration between academia, clinicians, public health stakeholders, policymakers, and implementing partners to ensure the success of the program and avert cervical cancer deaths.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top